Notas del episodio
This week, we have conversations with Eduardo Bravo, CEO of Citryll, and Dermot Tierney, COO of AMPLY Discovery.
Interview times:
02:53 Citryll
21:56 AMPLY Discovery
Citryll
Citryll’s recent Series B financing of €85m at the end of last year is helping to advance its first-in-class therapy targeting neutrophil extracellular traps (NETs).
Discovered in 2004, NETs are web-like structures released by white blood cells that are now understood to be fundamental drivers of inflammation - yet they've never been successfully targeted therapeutically.
Three major strategic investors are backing this novel biological approach, suggesting potential for a new ...
Palabras clave
biotechbiotechnologyAMRantimicrobial resistanceartificial intelligenceNETsneutrophil extracellular trapsCitryllAMPLY Discovery